Advance in Melanoma
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 25448
Special Issue Editors
Interests: melanoma; adjuvant therapy; immunotherapy; target therapy; skin lymphoma
Interests: melanoma; adjuvant therapy; immunotherapy; target therapy; skin lymphoma; dermoscopy
Special Issue Information
Dear Colleagues,
As you know, melanoma represents the skin cancer characterized by the potentially most unfavorable clinical course. Based on the natural history of the disease and the associated risks of progression and metastasis, four crucial articulations associated with potential impact on patient prognosis can be identified:
1) Identification of patients at risk that need periodic close monitoring by identifying associations between genotypic and phenotypic features;
2) Identification of predictive parameters on the risk of recurrence, progression, and metastasis, including reinterpretation of classical prognostic factors such as sentinel node biopsy;
3) Identification of parameters associated with a lower risk of recurrence after stage III adjuvant therapy, both phenotypical and genomics;
4) Identification of parameters associated with treatment response (stage IV metastatic melanoma) and residual disease persistence.
This Special Issue will address the most recent and relevant scientific findings regarding advances in melanoma.
Prof. Maria Teresa Fierro
Dr. Pietro Quaglino
Dr. Simone Ribero
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- adjuvant therapy
- immunotherapy
- target therapy
- skin lymphoma
- prognostic factors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.